CSBR241220P10000
- 0.00
- 0.000.00%
Champions Oncology Newsroom
Champions Oncology Analyst Ratings
Craig-Hallum Maintains Buy on Champions Oncology, Raises Price Target to $8
Craig-Hallum Maintains Champions Oncology(CSBR.US) With Buy Rating
Craig-Hallum Maintains Champions Oncology(CSBR.US) With Buy Rating
Craig-Hallum Maintains Champions Oncology(CSBR.US) With Buy Rating
Craig-Hallum Maintains Champions Oncology(CSBR.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Inotiv (NOTV), Ascendis Pharma (ASND) and Champions Oncology (CSBR)
Champions Oncology Upgraded to Buy by Craig-Hallum
Craig-Hallum Initiates Champions Oncology(CSBR.US) With Buy Rating, Announces Target Price $6
Champions Oncology Analyst Ratings
Craig-Hallum Maintains Champions Oncology(CSBR.US) With Buy Rating
Craig-Hallum Maintains Champions Oncology(CSBR.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Harrow Health (HROW), Accolade (ACCD) and Champions Oncology (CSBR)
Champions Oncology Analyst Ratings
Analysts' Top Healthcare Picks: Acurx Pharmaceuticals (ACXP), Champions Oncology (CSBR)
Craig Hallum Trims Champions Oncology Price Target to $9 From $10, Maintains Buy Rating
Analysts Offer Insights on Healthcare Companies: Champions Oncology (CSBR), Walgreens Boots Alliance (WBA) and Harrow Health (HROW)
Roth MKM Maintains Buy on Champions Oncology, Lowers Price Target to $7.5
Champions Oncology Analyst Ratings
Benchmark Co. Keeps Their Hold Rating on Champions Oncology (CSBR)